TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29044488

Group type: EXPERIMENTAL
Intervention: Nail plate replaced after nail-bed repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nail plate discarded after nail-bed repair
Number of subjects: 60
Study: 23980523

Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 697

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 697

Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 697
Study: 22621465

Group type: EXPERIMENTAL
Intervention: New methadone formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Previous reference formulation of methadone
Number of subjects: 24
Study: 20458256

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study: 18717675

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser phototherapy alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of 308-nm excimer laser phototherapy and topical hydrocortisone 17-butyrate cream
Number of subjects: 84
Study: 15666233

Group type: EXPERIMENTAL
Intervention: Protocol A (serial scanning of the head and spiral scans of thorax, abdomen/pelvis and spine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Protocol B (spiral scanning of all body regions without gantry angulation or arm elevation)
Number of subjects: 80
Study: 11844898

Group type: EXPERIMENTAL
Intervention: 80 mg eletriptan
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: 40 mg eletriptan
Number of subjects: 733

Group type: COMPARATOR
Intervention: Cafergot (1 mg ergotamine tartrate with 100 mg caffeine)
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Both doses of eletriptan
Number of subjects: 733
Study: 10421300

Group type: COMPARATOR
Intervention: Leg training (n=31)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Arm training (n=33)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Control group (n=37)
Number of subjects: 101
Study: 7588662

Group type: EXPERIMENTAL
Intervention: Intravenous maintenance anaesthesia (alfentanil infusion 1-1.5 micrograms kg‐1 min‐1, midazolam injections 2.5-5 mg h‐1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhalational maintenance anaesthesia (isoflurane up to 2%)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (125 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Inhalational anaesthesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intravenous anaesthesia
Number of subjects: 42
Study: 2113599

Group type: EXPERIMENTAL
Intervention: pH-stat management with arterial carbon dioxide tension at 71.1 mm Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: pH-stat management with arterial carbon dioxide tension at 46.1 mm Hg
Number of subjects: 9
Study: 7248984

Group type: EXPERIMENTAL
Intervention: Postmastectomy chemotherapy for 2 years
Number of subjects: 433
Study: 30885760

Group type: EXPERIMENTAL
Intervention: Picosecond alexandrite laser (PSAL)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL)
Number of subjects: 56
Study: 31088397

Group type: EXPERIMENTAL
Intervention: Patient involvement in shared-decision-making (SDM) regarding deprescribing; 19 patients interviewed, 18 fully trusted their GP, 17 participated in SDM before the study.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative assessment of attitudes, beliefs, and concerns towards deprescribing.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Predefined statements rated by patients regarding their attitudes towards deprescribing.
Number of subjects: 22
Study: 28750974

Group type: EXPERIMENTAL
Intervention: Kinesiology Tape Intervention (KTI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Kinesiology Tape Placebo (KTP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Comparison between KTI and KTP
Number of subjects: 34
Study: 26004248

Group type: EXPERIMENTAL
Intervention: Higher stress self-efficacy
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Stress perceived helplessness
Number of subjects: 978
Study: 23320821

Group type: EXPERIMENTAL
Intervention: Lipoprotein lipase (LPL)
Number of subjects: 2708

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Adjustment for LPL
Number of subjects: 2708
Study: 21507578

Group type: EXPERIMENTAL
Intervention: Warm touch intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Behavior monitoring control group
Number of subjects: 68
Study: 19833962

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17714576

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study: 16160710

Group type: EXPERIMENTAL
Intervention: 600 mg/day mifepristone for 8 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 30
Study: 12838495

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study: 9888122

Group type: EXPERIMENTAL
Intervention: Attendance feedback and prompts to attend aftercare
Number of subjects: 41

Group type: COMPARATOR
Intervention: No feedback and no prompts
Number of subjects: 41
Study: 8713566

Group type: EXPERIMENTAL
Intervention: Quinolone (n = 12)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Macrolide (n = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group cA (10 fertile men without chronic BP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group cB (10 patients affected by chronic abacterial prostatitis)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group cC (10 not-AT-treated BP patients)
Number of subjects: 22
Study: 2060529

Group type: EXPERIMENTAL
Intervention: pyrimethamine p.o./clindamycin i.v. and then p.o.
Number of subjects: 33

Group type: COMPARATOR
Intervention: pyrimethamine p.o./sulfadiazine p.o.
Number of subjects: 33
Study: 6660475

Group type: EXPERIMENTAL
Intervention: Innovar with Atropine
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Innovar without Atropine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Dolantin/Atosil
Number of subjects: 101
Study: 30937920

Group type: EXPERIMENTAL
Intervention: CBPA resource with training
Number of subjects: 83

Group type: COMPARATOR
Intervention: CBPA resource without training (Control)
Number of subjects: 83
Study: 27529839

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab (IVR) monotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 50
Study: 26125261

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation with visual stimuli
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine drug treatment
Number of subjects: 116
Study: 23502661

Group type: EXPERIMENTAL
Intervention: Direct breastfeeding
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 25% dextrose solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 120
Study: 21623778

Group type: EXPERIMENTAL
Intervention: Baseline plasma adiponectin concentration
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Increasing adiponectin concentration over 3 months
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: T-allele carriers for rs1501299 and A-allele carriers for rs17300539
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Adiponectin levels
Number of subjects: 1200
Study: 19490053

Group type: EXPERIMENTAL
Intervention: Rufinamide 1600 mg twice daily
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Rufinamide (post hoc analysis excluding carbamazepine users)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo (post hoc analysis excluding carbamazepine users)
Number of subjects: 313
Study: 16724649

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 15221244

Group type: EXPERIMENTAL
Intervention: P. niruri (450 mg capsules, td)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 11514376

Group type: EXPERIMENTAL
Intervention: Head-up tilt (70 degrees) for up to 30 minutes
Number of subjects: 34
Study: 9207435

Group type: EXPERIMENTAL
Intervention: Filgrastim-primed autologous bone marrow transplantation (ABMT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Filgrastim-mobilized peripheral blood stem cell transplantation (PBSC)
Number of subjects: 55
Study: 8310874

Group type: EXPERIMENTAL
Intervention: Outpatient group counseling (two alternative forms)
Number of subjects: 0
Study: 3503108

Group type: EXPERIMENTAL
Intervention: Orally administered haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical medications in glaucomatous patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study: 31142873

Group type: EXPERIMENTAL
Intervention: Protective CVC (Certofix® protect)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Standard CVC (Certofix®)
Number of subjects: 680
Study: 28462565

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 32

Group type: COMPARATOR
Intervention: Athletic taping
Number of subjects: 32
Study: 28242103

Group type: EXPERIMENTAL
Intervention: Scanning instruction
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Drilling instruction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Free search
Number of subjects: 19
Study: 26233764

Group type: EXPERIMENTAL
Intervention: Numerical skills training program (twice a week for 2 months, 30 minutes per session)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study: 23522363

Group type: EXPERIMENTAL
Intervention: Noble metal ceramic single crowns
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Fixed dental prosthesis retainer crowns
Number of subjects: 233

Group type: COMPARATOR
Intervention: Bruxism (medical history)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Bruxism (signs and symptoms)
Number of subjects: 233
Study: 20467418

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROSI) 8 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 21
Study: 18297434

Group type: EXPERIMENTAL
Intervention: Transnasal EGD
Number of subjects: 781

Group type: COMPARATOR
Intervention: Oral EGD
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 781
Study: 16554952

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (800 IU daily)
Number of subjects: 2117

Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 2117
Study: 14576756

Group type: EXPERIMENTAL
Intervention: Oral daily supplementation with 0.5 mg cyanocobalamin, 0.8 mg folic acid and 3 mg vitamin B6 for 4 months
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 209
Study: 10526245

Group type: EXPERIMENTAL
Intervention: TRH (200 microg, intravenously administered)
Number of subjects: 10
Study: 8913433

Group type: EXPERIMENTAL
Intervention: Oral ftorafur (370 mg/m2) and leucovorin (20 mg/m2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard in-hospital i.v. protocol of 5-fluouracil and leucovorin
Number of subjects: 61
Study: 1895471

Group type: EXPERIMENTAL
Intervention: Continuous 2.0 mg/h morphine infusion
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Continuous 0.5 to 2 mg/h morphine infusion
Number of subjects: 230

Group type: COMPARATOR
Intervention: No morphine infusion (control group)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 230
Study: 6341015

Group type: EXPERIMENTAL
Intervention: Individualized dietary review and recommendations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group behavior modification meetings
Number of subjects: 40
Study: 30790163

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 40 ml bupivacaine 0.25%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline instillation (Control)
Number of subjects: 100
Study: 30444479

Group type: EXPERIMENTAL
Intervention: HF Radio Scalpel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 24
Study: 26908302

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS) 40 µg/dose
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (PCA) 1 mg/dose
Number of subjects: 1216
Study: 23529273

Group type: COMPARATOR
Intervention: Post-dialysis dosing of cinacalcet (group AD) administered 3 times/week by dialysis staff.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Daily home administration of cinacalcet (group D).
Number of subjects: 23

Group type: COMPARATOR
Intervention: Post-dialysis dosing of cinacalcet (group AD) in patients with less severe SHPT.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Daily home administration of cinacalcet (group D) in patients with less severe SHPT.
Number of subjects: 23
Study: 23018548

Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19727788

Group type: EXPERIMENTAL
Intervention: TEOAE testing in isolation room during non-peak hour (E1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEOAE testing in isolation room during peak hour (E2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEOAE testing at maternal bedside during non-peak hour (E3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEOAE testing at maternal bedside during peak hour (E4)
Number of subjects: 0
Study: 17340186

Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care Program for Preschoolers (MTFC-P)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Regular foster care condition
Number of subjects: 117

Group type: COMPARATOR
Intervention: Both groups (MTFC-P and Regular foster care)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: MTFC-P
Number of subjects: 117
Study: 16287602

Group type: EXPERIMENTAL
Intervention: Iscador Quercus spezial (IQ)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Purified mistletoe lectin (ML)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Mistletoe plant extract IQ depleted from ML
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 12016081

Group type: EXPERIMENTAL
Intervention: Patellar tendinitis group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patellofemoral pain group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 0
Study: 9804681

Group type: EXPERIMENTAL
Intervention: Topically applied emulsion of an analgesic ammonium solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 8747861

Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in TIA cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in lacunar infarction cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in large infarction cases
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carotid artery stenosis assessment in asymptomatic side
Number of subjects: 100
Study: 2695549

Group type: EXPERIMENTAL
Intervention: NaCl restriction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calcium (Ca) supplementation 1.5 g daily for 12 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calcium (Ca) supplementation 1 g daily for 8 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Potassium (K) supplementation with a nonchloride salt for 4 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 321087

Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg/day for three consecutive days every fortnight (study 1 and first half of study 2)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Levamisole given only when an episode of RAS occurred (study 3)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (control group in study 1 and first half of study 2)
Number of subjects: 124
Study: 31677995

Group type: EXPERIMENTAL
Intervention: Traditional method of vacuum assisted wound closure for 8 weeks; dressing changed 3 times weekly, at 125 mmHg, mode of 2 min off and 5 min on.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified method by switching off the device at the fifth week, applying traditional dressing for one week, then three weeks of vacuum wound closure.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (traditional method)
Number of subjects: 30
Study: 29462456

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2700 mg/day for 6 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 28893306

Group type: EXPERIMENTAL
Intervention: Monitored vitamin D supplementation (500 IU and an additional 150-300 IU/kg in human milk fortifiers or 190 IU/kg in milk formulas)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitored vitamin D supplementation
Number of subjects: 0
Study: 26289436

Group type: EXPERIMENTAL
Intervention: Leucine at 0.45 kcal/min (total 9.9 g, 40.5 kcal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Leucine at 0.15 kcal/min (total 3.3 g, 13.5 kcal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study: 24171964

Group type: EXPERIMENTAL
Intervention: rhTPO combined with glucocorticoid
Number of subjects: 62

Group type: COMPARATOR
Intervention: Glucocorticoid only
Number of subjects: 62
Study: 21173568

Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19047026

Group type: EXPERIMENTAL
Intervention: AUDIT-C group (nondrinkers)
Number of subjects: 13470

Group type: EXPERIMENTAL
Intervention: AUDIT-C group (low-level alcohol use)
Number of subjects: 13470

Group type: EXPERIMENTAL
Intervention: AUDIT-C group (mild alcohol misuse)
Number of subjects: 13470

Group type: EXPERIMENTAL
Intervention: AUDIT-C group (moderate alcohol misuse)
Number of subjects: 13470

Group type: COMPARATOR
Intervention: Oral hypoglycemics
Number of subjects: 13470
Study: 17156625

Group type: EXPERIMENTAL
Intervention: T(3) sympathectomy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: T(4) sympathectomy
Number of subjects: 106
Study: 12767415

Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate
Number of subjects: 251

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study: 11323338

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 180
Study: 8995350

Group type: EXPERIMENTAL
Intervention: Dios (Daflon 500 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Plac (placebo)
Number of subjects: 104
Study: 8127216

Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine (initial dose)
Number of subjects: 307981

Group type: EXPERIMENTAL
Intervention: Mycobacterium w vaccine (booster dose)
Number of subjects: 307981

Group type: COMPARATOR
Intervention: Placebo (initial dose)
Number of subjects: 307981

Group type: COMPARATOR
Intervention: Placebo (booster dose)
Number of subjects: 307981
Study: 3306131

Group type: EXPERIMENTAL
Intervention: Sandwich chemotherapy (administered between surgery and postoperative irradiation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with CCNU and vincristine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandwich chemotherapy (as administered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reduced radiotherapy doses to the supratentorial area and to the spine in low risk patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classical risk factors
Number of subjects: 0
Study: 2397975

Group type: EXPERIMENTAL
Intervention: Pulsed electrical field treatment administered over 36 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 30
Study: 4922754

Group type: EXPERIMENTAL
Intervention: Folic acid 15 mg daily
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31228771

Group type: EXPERIMENTAL
Intervention: Regular screening for CAD using noninvasive tests prior to wait-listing and annually after wait-listing until transplantation.
Number of subjects: 3306

Group type: COMPARATOR
Intervention: Eliminating screening tests for occult CAD after wait-listing.
Number of subjects: 3306

Group type: EXPERIMENTAL
Intervention: Regular screening for CAD.
Number of subjects: 3306
Study: 28108790

Group type: EXPERIMENTAL
Intervention: Apnea Sleep Position Trainer (Android) and SomnoPose‐Sleep Position Monitor (iOS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control polysomnography (PSG) after 1 month
Number of subjects: 33
Study: 26145272

Group type: EXPERIMENTAL
Intervention: Direct exposure to 33% fat-reduced variant
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Direct exposure to 28% sugar-reduced variant
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control group (standard variant)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Stepwise exposure (more reduced variants)
Number of subjects: 219
Study: 23459887

Group type: EXPERIMENTAL
Intervention: Home visits and phone calls (4 home visits and 4 phone calls over 6 months)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional follow up with no visits or phone calls
Number of subjects: 200
Study: 21164355

Group type: EXPERIMENTAL
Intervention: hApoA-I overexpression via intraportal/vector administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hApoA-I overexpression via intramuscular/vector administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: hApoA-I overexpression (both routes)
Number of subjects: 0
Study: 19111806

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy, chemotherapy, or a combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 0